Risk tool identifies candidates for adjuvant radiotherapy in prostate cancer – Combines tumour pathology, genomic data to reduce over-treatment

A novel risk stratification tool that combines pathologic tumour characteristics with data from the Decipher genomic classifier may help predict 5- and 10-year metastasis-free survival in patients with aggressive prostate cancer after radical prostatectomy. It can also be used to identify patients with prostate cancer who could benefit from postoperative adjuvant radiotherapy, thereby reducing risk of over-treatment, adverse effects, and clinical recurrence.
MedPage Today